Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses.
epithelial ovarian cancer
high-grade serous ovarian cancer
inflammatory soluble biomarkers
interleukin 6
platinum resistance
progression-free survival
regulatory T cells
tumour necrosis factor 2 receptor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jan 2023
21 Jan 2023
Historique:
received:
10
12
2022
revised:
14
01
2023
accepted:
19
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
We hypothesised that the inclusion of immunosuppressive and inflammatory biomarkers in HGSOC patients would improve the sensitivity and specificity of the preoperative marker prediction of malignancy in patients with ovarian masses. We tested a panel of 29 soluble immune factors by multiplex bead immunoassay and 16 phenotypic T cell markers by flow cytometry in pre-treatment blood samples from 66 patients undergoing surgery for suspected ovarian cancer or ovarian cancer risk reduction. The potential diagnostic utility of all parameters was explored using Volcano plots, principal component analysis (PCA) and receiver operator characteristic (ROC) analysis. We also assessed the effect of culturing PBMCs from 20 healthy donors in the presence of malignant ascites fluid. The combination of TNFR2
Identifiants
pubmed: 36765633
pii: cancers15030667
doi: 10.3390/cancers15030667
pmc: PMC9913655
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Biomed Res Int. 2015;2015:413076
pubmed: 26137480
Eur Cytokine Netw. 2013 Jul-Sep;24(3):106-13
pubmed: 24197277
Sci Rep. 2020 Feb 10;10(1):2213
pubmed: 32042020
J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88
pubmed: 20082099
Membranes (Basel). 2021 Apr 24;11(5):
pubmed: 33923292
Ann Oncol. 2015 Oct;26(10):2141-9
pubmed: 26216383
Cancer Immunol Immunother. 2015 Nov;64(11):1475-85
pubmed: 26280204
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Sci Rep. 2013 Nov 06;3:3153
pubmed: 24193319
Tumour Biol. 2010 Apr;31(2):113-9
pubmed: 20358424
Neuro Endocrinol Lett. 2010;31(3):375-83
pubmed: 20588232
Cell Cycle. 2005 Feb;4(2):217-20
pubmed: 15655344
Clin Cancer Res. 2006 Sep 1;12(17):5055-63
pubmed: 16951221
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
Sci Signal. 2017 Jan 17;10(462):
pubmed: 28096506
Am J Hematol. 2014 Aug;89(8):795-802
pubmed: 24757092
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Hum Reprod. 1989 Jan;4(1):1-12
pubmed: 2651469
J Adv Pract Oncol. 2015 Sep-Oct;6(5):435-40
pubmed: 27069736
Cancer. 2006 Feb 1;106(3):589-98
pubmed: 16369985
Front Immunol. 2022 Feb 16;13:835690
pubmed: 35251028
Cancer Res. 2003 Jul 1;63(13):3695-700
pubmed: 12839961
Anticancer Res. 2009 Aug;29(8):2875-84
pubmed: 19661290
Cell Cycle. 2017 Oct 2;16(19):1727-1728
pubmed: 28820313
Cytokine. 2012 May;58(2):133-47
pubmed: 22349527
Biomed Pharmacother. 2018 Dec;108:1415-1424
pubmed: 30372844
Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34
pubmed: 27898521
Gynecol Oncol. 1997 Jul;66(1):27-30
pubmed: 9234916
Cytometry B Clin Cytom. 2007;72 Suppl 1:S14-22
pubmed: 17803189
Eur J Obstet Gynecol Reprod Biol. 2018 Dec;231:35-42
pubmed: 30317143
Transplantation. 2006 Oct 15;82(7):953-64
pubmed: 17038912
J Immunol. 2013 Feb 1;190(3):1076-84
pubmed: 23277487
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Sci Signal. 2017 Jan 17;10(462):
pubmed: 28096513
Obstet Gynecol Sci. 2022 Jul;65(4):346-354
pubmed: 35443557
Cell Mol Immunol. 2005 Oct;2(5):365-72
pubmed: 16368063
Nat Rev Cancer. 2007 Nov;7(11):880-7
pubmed: 17957190
Gynecol Oncol. 2008 Feb;108(2):402-8
pubmed: 18061248
Immunity. 2008 Jun;28(6):870-80
pubmed: 18513999
Carcinogenesis. 2021 Apr 17;42(3):327-343
pubmed: 33608706
Curr Med Chem. 2018;25(36):4785-4806
pubmed: 28707587
Front Immunol. 2017 Nov 06;8:1482
pubmed: 29163543
Int J Biol Sci. 2012;8(9):1248-53
pubmed: 23136553
Evid Rep Technol Assess (Full Rep). 2006 Feb;(130):1-145
pubmed: 17854238
Biosci Biotechnol Biochem. 2022 Feb 24;86(3):351-361
pubmed: 35015831
J Ovarian Res. 2019 Mar 27;12(1):28
pubmed: 30917847
Talanta. 2013 Sep 30;114:95-102
pubmed: 23953447
Cancer Sci. 2016 Sep;107(9):1173-8
pubmed: 27297561
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9
pubmed: 22918931
Trends Mol Med. 2017 Nov;23(11):1037-1046
pubmed: 29032004
BMC Cancer. 2015 Jul 01;15:492
pubmed: 26122176
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Cancer Lett. 2010 Sep 1;295(1):110-23
pubmed: 20236757
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2285-95
pubmed: 25169975
Trends Cancer. 2017 Feb;3(2):137-148
pubmed: 28718444
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Front Pharmacol. 2021 May 17;12:688625
pubmed: 34079469
BMC Genomics. 2013 Jul 26;14:508
pubmed: 23889749
Nat Rev Immunol. 2006 Apr;6(4):295-307
pubmed: 16557261
Curr Pharm Des. 2012;18(25):3816-27
pubmed: 22591418
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
J Immunol. 2010 Jul 1;185(1):174-82
pubmed: 20525892
Int J Mol Sci. 2017 May 17;18(5):
pubmed: 28513532
Mol Cancer Res. 2011 Dec;9(12):1718-31
pubmed: 21994466
Front Oncol. 2013 Sep 25;3:256
pubmed: 24093089
Ann Transl Med. 2021 May;9(9):788
pubmed: 34268401
Biomolecules. 2021 Sep 18;11(9):
pubmed: 34572592
Cells. 2022 Jun 17;11(12):
pubmed: 35741080
Cancers (Basel). 2020 Jul 17;12(7):
pubmed: 32708856
Gynecol Oncol. 2009 Jan;112(1):40-6
pubmed: 18851871
Cytokine. 2015 May;73(1):108-13
pubmed: 25743245
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7
pubmed: 15824174
Clin Immunol. 2013 Oct;149(1):97-110
pubmed: 23948613
J Mol Med (Berl). 2013 Mar;91(3):357-68
pubmed: 23052480
Front Oncol. 2018 Dec 04;8:577
pubmed: 30564556
Arthritis Res Ther. 2006;8 Suppl 2:S2
pubmed: 16899106
Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):94-101
pubmed: 17118522
Br J Cancer. 2011 Mar 1;104(5):863-70
pubmed: 21304524